CClinicalTrials.gg
RecruitingNCT06441864Updated Mar 12, 2026

Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder

An interventional study of Cognitive Behavioral Therapy for Nightmares in Nightmare, Nightmare Disorder With Associated Other Sleep Disorder and REM Sleep Behavior Disorder, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by University of Utah · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD). People with RBD will be enrolled in the study along with their family members (a partner or other family member residing in the same home). All participants will receive the treatment via videoconference and will complete 2 assessments. Participants with RBD will attend 7 sessions, and their family members will attend 2 of those sessions with them.

02

Conditions studied

  • Nightmare
  • Nightmare Disorder With Associated Other Sleep Disorder
  • REM Sleep Behavior Disorder

Keywords

  • Imagery Rehearsal Therapy
  • Cognitive Behavioral Therapy for Nightmares
03

In context

REM Sleep Behavior Disorder

97 studies on the registry are indexed under REM Sleep Behavior Disorder; 41 are open to participants now.

This study's planned enrollment of 20 is below the median of 44 across 49 interventional studies indexed under REM Sleep Behavior Disorder.

Browse REM Sleep Behavior Disorder studies →

Lead sponsor

University of Utah is the lead sponsor of 969 studies on the registry; 178 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 62 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of isolated RBD or RBD secondary to neurodegenerative disease
  • Age 18 or older
  • Speak, read, and write English
  • Live in the United States
  • Nightmare frequency ≥3 times per week
  • Disturbing Dream and Nightmare Severity Index score indicative of nightmare disorder
  • Sleep, neurological, and psychiatric medications stable for at least 1 month and willing to keep medications stable through the course of the study
  • Live with a family member who is willing to participate in the study

Exclusion Criteria:

  • Possible dementia
  • Narcolepsy
  • Posttraumatic stress disorder
  • Previous behavioral treatment for nightmares
  • Currently engaged in sleep- or trauma-focused psychotherapy
  • Taking a medication that could cause RBD, if the medication was started prior to onset of RBD symptoms

Inclusion Criteria (Family Members):

  • Live with a family member who meets all of the above criteria
  • Age 18 or older
  • Speak, read, and write English
  • Live in the United States
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    2-week baseline

    Participants will receive treatment after a 2-week baseline assessment period

    Behavioral: Cognitive Behavioral Therapy for Nightmares

  • Experimental
    4-week baseline

    Participants will receive treatment after a 4-week baseline assessment period

    Behavioral: Cognitive Behavioral Therapy for Nightmares

Interventions

  • BehavioralCognitive Behavioral Therapy for Nightmares

    The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. Family members will attend 2 of the 7 treatment sessions. During the sessions, participants will learn techniques for managing and changing nightmares.

    Also known as: Imagery Rehearsal Therapy

06

What researchers measure

Primary outcomes

  1. Disturbing Dream and Nightmare Severity Index (DDNSI)

    The DDNSI is a questionnaire which measures the severity of nightmares.

    Time frame: Baseline and posttreatment

  2. Nightmare frequency (sleep diary)

    The number of nightmares experienced each day will be collected on daily sleep diaries completed during each assessment period.

    Time frame: Baseline and posttreatment

07

Study locations

1 of 1 sites recruiting
  • University of Utah
    Salt Lake City, Utah 84108, United States
    • Jennifer Mundt, PhD · Contact · RBDstudy@utah.edu · 801-646-8287
    • Jennifer Mundt, PhD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06441864
Lead sponsor
University of Utah
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Jul 15, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Mar 12, 2026

Study contacts

Jennifer Mundt, PhD
Contact
RBDstudy@utah.edu
801-646-8287

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion